Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals Holdings (CRBP)
:CRBP
CRBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.64 - $61.90
Previous CloseN/A
Volume39.58K
Average Volume (3M)204.63K
Market Cap
$77.06M
Enterprise Value-$2.39M
Total Cash (Recent Filing)$303.02K
Total Debt (Recent Filing)$638.08K
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 13, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding12,232,228
10 Day Avg. Volume190,569
30 Day Avg. Volume204,634
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$53.63Price Target Upside751.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Announces Board Member Departure
PremiumCompany Announcements
Corbus Pharmaceuticals Appoints Ian Hodgson as COO
PremiumCompany Announcements
Corbus Pharmaceuticals Advances in Oncology and Obesity
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q4 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Antibody-Drug Conjugates MarketAnalyst holds a bullish view on the antibody-drug conjugate (ADC) market, offering significant growth potential for investors.
Drug DevelopmentCorbus Pharmaceuticals announced the initiation of a Phase 1 trial for CRB-913, a promising treatment for obesity, showcasing their ongoing advancements in drug development.
Financial PerformanceCorbus Pharmaceuticals ended the fourth quarter with $149.1 million in cash, providing a strong financial position to fund operations.
Bears Say
Adverse EventsConcerns exist regarding neuropsychiatric adverse events associated with CB1R inverse agonists, potentially impacting CRB-913's development.
Drug Sales ProjectionsCRB-913 peak sales were lowered to $1.2B, which could impact the perceived future revenue potential.
Market SentimentThe short interest in Corbus Pharmaceuticals is 23.2% of the float, indicating a significant portion of the market is betting against the stock.
---
Ownership Overview
31.61% Insiders
8.60% Mutual Funds
0.07% Other Institutional Investors
48.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBP FAQ
What was Corbus Pharmaceuticals Holdings’s price range in the past 12 months?
Corbus Pharmaceuticals Holdings lowest stock price was $4.64 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals Holdings’s market cap?
Corbus Pharmaceuticals Holdings’s market cap is $77.06M.
When is Corbus Pharmaceuticals Holdings’s upcoming earnings report date?
Corbus Pharmaceuticals Holdings’s upcoming earnings report date is May 13, 2025 which is in 20 days.
How were Corbus Pharmaceuticals Holdings’s earnings last quarter?
Corbus Pharmaceuticals Holdings released its earnings results on Mar 11, 2025. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$1.265 by $0.485.
Is Corbus Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Corbus Pharmaceuticals Holdings’s price is currently Undervalued.
Does Corbus Pharmaceuticals Holdings pay dividends?
Corbus Pharmaceuticals Holdings does not currently pay dividends.
What is Corbus Pharmaceuticals Holdings’s EPS estimate?
Corbus Pharmaceuticals Holdings’s EPS estimate is -1.22.
How many shares outstanding does Corbus Pharmaceuticals Holdings have?
Corbus Pharmaceuticals Holdings has 12,232,228 shares outstanding.
What happened to Corbus Pharmaceuticals Holdings’s price movement after its last earnings report?
Corbus Pharmaceuticals Holdings reported an EPS of -$0.78 in its last earnings report, beating expectations of -$1.265. Following the earnings report the stock price went up 1.325%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in CRBP
---
Corbus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.63 (751.27% Upside)
$53.63 (751.27% Upside)
Blogger Sentiment
Neutral
CRBP Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 151.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.94%
12-Months-Change
Fundamentals
Return on Equity
-59.34%
Trailing 12-Months
Asset Growth
451.35%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
---
CRBP Stock 12 Month Forecast
Average Price Target
$53.63
▲(751.27% Upside)
Technical Analysis
Assertio Therapeutics
―
Adicet Bio
―
Exagen
―
Pyxis Oncology
―
Acrivon Therapeutics, Inc.
―
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-30.09%
reiterated a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -30.09% per trade.
---